Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL vs FIRMAGON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.
Cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients,Colonoscopy preparation in patients with renal impairment or electrolyte abnormalities (off-label)
FDA-approved for advanced prostate cancer (hormone-sensitive, metastatic or locally advanced),Off-label: Treatment of uterine fibroids, endometriosis, and precocious puberty
For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.
For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.
PEG-3350: not applicable (non-absorbed). Bisacodyl: terminal half-life 8–16 hours; clinical effect peaks within 6–12 hours.
Terminal elimination half-life is approximately 63 days after subcutaneous administration in patients with prostate cancer, allowing for monthly dosing schedules.
PEG-3350 is not metabolized; excreted unchanged in feces. Bisacodyl is metabolized in the liver and small intestine to its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane, by ester hydrolysis. Electrolytes are absorbed or secreted by normal physiological mechanisms.
Degraded into peptides and amino acids; not a substrate for CYP450 enzymes.
PEG-3350 is not absorbed, excreted unchanged in feces. Electrolytes (sodium chloride, sodium bicarbonate, potassium chloride) are absorbed and renally excreted; bisacodyl is primarily excreted as glucuronide conjugates in feces (biliary) and urine (renal). Approximately 95% of bisacodyl is recovered in feces, 5% in urine.
Primarily hepatobiliary; about 90% of the dose is eliminated in feces as unchanged drug, with less than 5% excreted renally as unchanged drug and metabolites.
PEG-3350: negligible (non-absorbed). Bisacodyl: ~90% bound to plasma proteins.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
PEG-3350: not distributed (non-absorbed). Bisacodyl: Vd approximately 0.4–0.6 L/kg, indicating moderate tissue distribution.
Volume of distribution is approximately 10 L, indicating limited extravascular distribution consistent with a large peptide.
PEG-3350: negligible systemic absorption (<0.2%). Bisacodyl: oral bioavailability 15–30% due to first-pass metabolism; rectal bioavailability ~50%.
Subcutaneous administration: Bioavailability is approximately 50% relative to intravenous administration, with absorption characterized by a slow and sustained release profile.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to risk of electrolyte disturbances. In moderate impairment (Cr Cl 30-50 m L/min): use with caution, monitor electrolytes. No dose adjustment specified by manufacturer for mild impairment.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min). Use with caution.
No specific dose adjustment required for hepatic impairment based on Child-Pugh class. However, use with caution in severe hepatic impairment due to potential for encephalopathy from electrolyte shifts.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Not FDA-approved for children <2 years. For children 2-11 years: PEG-3350 plus electrolytes 75-100 m L/kg/dose orally, up to 4 L, for colonoscopy preparation. Bisacodyl tablets: children 6-11 years: 2.5-5 mg orally at bedtime day before procedure. Weight-based: not standardized; refer to specific pediatric protocols.
Safety and efficacy in pediatric patients have not been established. Not indicated for use in children.
Use with caution due to increased risk of electrolyte imbalance and dehydration. No specific dose reduction recommended; however, consider lower volume (2 L) split-dose regimen. Monitor renal function and electrolytes before and after procedure.
No specific dose adjustment is recommended for elderly patients. Monitor for cardiovascular events and changes in bone density due to androgen deprivation.
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. There have been reports of significant fluid shifts, severe electrolyte abnormalities (including hypokalemia, hyponatremia), and dehydration in patients treated with this product. The risk is increased in patients with renal insufficiency, electrolyte abnormalities, or those taking concomitant medications that affect electrolytes. Monitor and correct fluid and electrolyte disturbances before use.
Increased risk of QT interval prolongation; use caution in patients with congenital long QT syndrome, electrolyte abnormalities, or concomitant use of QT-prolonging drugs. Also, hypersensitivity reactions including anaphylaxis have been reported.
Risk of electrolyte abnormalities and dehydration; correct before use,Use with caution in patients with renal impairment, electrolyte disturbances, or taking diuretics, ACE inhibitors, or NSAIDs,Risk of serious arrhythmias due to electrolyte imbalance,Possible colonic mucosal ulcerations (aphthoid ulcers) with bisacodyl,Gag reflex may be impaired in elderly, debilitated, or patients with swallowing disorders; risk of aspiration,May cause Mallory-Weiss tear or esophageal perforation if vomiting occurs,Monitor for QT prolongation in at-risk patients
QT prolongation and ventricular arrhythmias (especially with hypokalemia or bradycardia),Hypersensitivity reactions (urticaria, angioedema, anaphylaxis),Tumor flare reaction (transient worsening of symptoms due to initial testosterone surge) - less common with degarelix compared to Gn RH agonists,Loss of bone mineral density with long-term use,Injection site reactions (pain, erythema, nodule, necrosis),Increased hepatic enzymes (transient and usually asymptomatic),Hyperglycemia and increased risk of diabetes (monitor blood glucose),Cardiovascular risks (myocardial infarction, stroke) in patients with pre-existing conditions
Known hypersensitivity to any component,Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis, toxic megacolon,Significant electrolyte abnormalities (e.g., severe hypokalemia, hyponatremia),Renal impairment (e.g., creatinine clearance < 30 m L/min) for formulations with high PEG-3350 content (note: this product contains lower PEG dose, but caution still warranted),Pregnancy (relative contraindication; use only if clearly needed),Patients with impaired consciousness
Hypersensitivity to degarelix or any component of the formulation,Women of reproductive potential (pregnancy category X; can cause fetal harm),Severe renal impairment (Cr Cl < 30 m L/min) - insufficient data,Severe hepatic impairment (Child-Pugh class C) - not studied
Avoid solid foods, dairy, and red/purple colored liquids during preparation. Only clear liquids (water, clear broth, apple juice, gelatin, tea or coffee without cream) are permitted until after the procedure.
No significant food interactions. Avoid grapefruit juice if also taking certain antiarrhythmics or other QT-prolonging drugs. Maintain adequate calcium and vitamin D intake if at risk for bone loss.
First trimester: Minimal systemic absorption; no known teratogenic effects. Second/third trimester: Avoid use due to risk of electrolyte imbalance and fluid shifts; not associated with congenital anomalies.
FIRMAGON (degarelix) is contraindicated in pregnancy. Gn RH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal studies and its mechanism of action, degarelix is expected to increase the risk of first trimester pregnancy loss. Adequate human data are not available, but the drug should be avoided during pregnancy. If exposure occurs, inform the patient of the potential hazard.
Bisacodyl and polyethylene glycol are not excreted in breast milk in significant amounts; M/P ratio unknown. Minimal systemic absorption suggests low risk. Use with caution due to potential gastrointestinal effects in infant.
It is not known whether degarelix is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from degarelix, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No standard dose adjustments established; avoid use in pregnancy due to lack of safety data. If used, standard dosing for bowel preparation should be individualized with close monitoring.
No dosage adjustment studies have been conducted in pregnant women. Degarelix is contraindicated in pregnancy, and use should be avoided. If inadvertent exposure occurs, no specific dose adjustment is recommended; instead, the drug should be discontinued and the patient counseled about fetal risks.
This combination is used for colonoscopy preparation. Ensure adequate hydration and renal function assessment; avoid in patients with ileus, GI obstruction, or significant electrolyte abnormalities. Bisacodyl is a stimulant laxative that may cause cramping. Administer in divided doses as per protocol.
FIRMAGON (degarelix) is a Gn RH antagonist indicated for advanced prostate cancer. It does not cause testosterone flare like Gn RH agonists. Monitor serum calcium in patients with bone metastases due to risk of hypercalcemia. Injection site reactions are common; rotate sites and apply warm compresses. Use with caution in patients with congenital long QT syndrome or those on Class IA/III antiarrhythmics.
Drink plenty of clear liquids to stay hydrated.,Follow the exact dosing schedule provided by your doctor.,Expect frequent, watery bowel movements; stay near a restroom.,Do not eat solid foods during the preparation; only clear liquids.,Notify your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
This medication is given as an injection under the skin, usually every month.,It may cause injection site reactions like redness, swelling, or pain; applying a warm compress can help.,You may experience hot flashes, decreased libido, or erectile dysfunction.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or unusual bleeding/bruising.,Regular blood tests are needed to monitor response and side effects.
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL vs FIRMAGON, answered by our medical review team.
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is a Electrolyte that works by Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.. FIRMAGON is a GnRH Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL and FIRMAGON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is: For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.. The standard adult dose of FIRMAGON is: For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL and FIRMAGON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is classified as Category A/B. First trimester: Minimal systemic absorption; no known teratogenic effects. Second/third trimester: Avoid use due to risk of electrolyte imbalance and fluid shifts; not associated . FIRMAGON is classified as Category C. FIRMAGON (degarelix) is contraindicated in pregnancy. GnRH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.